News & Updates
Filter by Specialty:
Guselkumab yields durable benefit in biologic-naïve PsA patients
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.
Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
22 Nov 2021
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
13 Nov 2021
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
02 Nov 2021
ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis
Interleukin-17 inhibition with the biologic disease-modifying antirheumatic drug (DMARD) secukinumab appears to produce a substantial reduction in synovitis in psoriatic arthritis, in addition to improvements in the signs and symptoms of the disease, according to the results of the phase III ULTIMATE.